Stockscreener 앱 받기
5.90
0.34%
-0.02
시간 외 거래:
5.90
전일 마감가:
$5.92
열려 있는:
$5.92
하루 거래량:
1.41M
Relative Volume:
0.31
시가총액:
$614.67M
수익:
$234.04M
순이익/손실:
$-323.92M
주가수익비율:
-1.3024
EPS:
-4.53
순현금흐름:
$-223.46M
1주 성능:
+11.32%
1개월 성능:
+13.68%
6개월 성능:
+63.43%
1년 성능:
-25.22%
1일 변동 폭
$5.835
$5.94
1주일 범위
$4.68
$6.09
52주 변동 폭
$2.30
$9.745
Revance Therapeutics Inc Stock (RVNC) Company Profile
명칭
Revance Therapeutics Inc
전화
(615) 724-7755
주소
1222 DEMONBREUN STREET, NASHVILLE, CA
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-16 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-22 | 개시 | Goldman | Buy |
| 2021-10-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | 재확인 | Needham | Buy |
| 2020-08-11 | 재개 | Mizuho | Buy |
| 2020-03-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-12-02 | 개시 | Goldman | Buy |
| 2019-10-30 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-02-15 | 개시 | Wells Fargo | Market Perform |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
| 2018-11-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2018-09-17 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | 재확인 | Mizuho | Buy |
| 2018-03-27 | 개시 | Needham | Buy |
| 2018-03-05 | 개시 | Goldman | Buy |
| 2018-01-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2017-12-06 | 개시 | Guggenheim | Buy |
| 2017-12-06 | 재확인 | Mizuho | Buy |
| 2017-11-27 | 개시 | Barclays | Overweight |
| 2017-11-17 | 개시 | Mizuho | Buy |
| 2017-08-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Revance Therapeutics Inc 주식(RVNC)의 최신 뉴스
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders - GlobeNewswire Inc.
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in September - MarketBeat
AQR Capital Management LLC Has $517,000 Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Algert Global LLC Sells 127,260 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com - MarketBeat
(RVNC) Investment Report - Stock Traders Daily
Revance Therapeutics, Crown Labs tender offer extended until Oct. 18 - MSN
Renaissance Technologies LLC Acquires 198,300 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics extends tender offer amid Teoxane dispute - Investing.com
Revance Therapeutics merger delayed due to alleged contract breach - The Business Journals
Revance Therapeutics (NASDAQ:RVNC) Shares Down 4.6%Should You Sell? - MarketBeat
William Blair Downgrades Revance Therapeutics (RVNC) - MSN
Revance Therapeutics extends tender offer amid Teoxane dispute By Investing.com - Investing.com UK
Revance Therapeutics, Crown Labs Extend Tender Offer Start Deadline to Oct. 18 >RVNC - MarketWatch
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Gap Down to $5.36 - MarketBeat
Revance Therapeutics, Inc. (NASDAQ:RVNC) is Stonepine Capital Management LLC's 5th Largest Position - MarketBeat
Revance Therapeutics' SWOT analysis: tender offer shakes up aesthetics stock - Investing.com
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround - MSN
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm - The Malaysian Reserve
Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares (RVNC) - Seeking Alpha
When (RVNC) Moves Investors should Listen - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, GATO, RFL on Behalf of Shareholders - Longview News-Journal
Revance Therapeutics Inc (RVNC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
0.26%
자본화:
|
볼륨(24시간):